US2019248739A1PendingUtilityA1
Salts and prodrugs of 1-methyl-d-tryptophan
Est. expiryJul 24, 2035(~9 yrs left)· nominal 20-yr term from priority
A61P 37/02A61P 43/00A61P 37/04A61P 35/00A61P 31/00A61K 31/285C07C 309/04C07D 401/12A61K 31/404C07D 405/12C07F 9/65742A61K 9/48C07C 309/20C07D 209/20C07K 5/06104C07K 5/06086C07K 5/06078C07K 5/0606C07K 5/06043C07K 5/06034C07K 5/06026C07D 209/24
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.
Claims
exact text as granted — not AI-modified1 - 34 . (canceled)
35 . A method of use of a pharmaceutical composition comprising benzyl N α -(tert-butoxycarbonyl)-1-methyl-D-tryptophanate to treat immunosuppression associated with HIV-1 infection in a subject in need thereof, comprising orally administering a sufficient amount of the composition to the subject in an appropriate pharmaceutical form or vehicle.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.